Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Mar 27, 2022

Keywords

ClinConnect Summary

The Change Database is a clinical study that aims to gather information about patients with chronic thromboembolic pulmonary hypertension (CTEPH) in China. CTEPH is a condition where blood clots in the lungs cause high blood pressure, which can lead to serious health issues. This trial will help researchers understand how common CTEPH is, how it is treated, and what the long-term outcomes are for patients. The study is currently looking for participants, and anyone aged 51 and older who has been diagnosed with CTEPH and is willing to give their consent may be eligible to join.

Participants in this study will not receive any specific treatment; instead, they will contribute to a database that collects important health information over time. This data will help improve the understanding and management of CTEPH for future patients. It's important to note that patients who have another main cause of pulmonary hypertension or are currently involved in another clinical trial with an unknown drug cannot participate. If you or a loved one is interested in contributing to this important research, discussing it with a healthcare provider can provide more personalized information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must be diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH)
• • 2. Patients must be willing to provide informed consent
• 3. Patients must meet the following criteria for CTEPH:
• • a mean pulmonary artery pressures (mPAP) ≥20 mmHg combined with a pulmonary vascular resistance (PVR) ≥ 3 WU and pulmonary arterial wedge pressure (PAWP)≤ 15 mmHg documented at right heart catheterization with radiographic evidence of organized thrombi involving the pulmonary arteries after 3 months of effective anticoagulation.
• Exclusion Criteria:
• • 1. Main cause of PH other than CTEPH
• • 2. Participation in a therapeutic clinical trial with an unknown drug;
• • 3. Withdrawal or lack of informed consent.